Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model
Drug-eluting bead transarterial chemoembolization (DEB-TACE) has been widely used in the treatment of liver cancer; however, the utilization rate of chemotherapeutic drugs after embolization is low. Chemotherapy resistance mediated by high nuclear factor E2-related factor 2 (NRF2) expression limits...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.906971/full |
| _version_ | 1811195267613982720 |
|---|---|
| author | Fanguang Meng Fanguang Meng Yuyao Li Yuyao Li Qian Liu Liwei Sun Liwei Sun Hankang Wang Hankang Wang Xiaodong Li Xiaodong Li Guijie Li Feng Chen |
| author_facet | Fanguang Meng Fanguang Meng Yuyao Li Yuyao Li Qian Liu Liwei Sun Liwei Sun Hankang Wang Hankang Wang Xiaodong Li Xiaodong Li Guijie Li Feng Chen |
| author_sort | Fanguang Meng |
| collection | DOAJ |
| description | Drug-eluting bead transarterial chemoembolization (DEB-TACE) has been widely used in the treatment of liver cancer; however, the utilization rate of chemotherapeutic drugs after embolization is low. Chemotherapy resistance mediated by high nuclear factor E2-related factor 2 (NRF2) expression limits DEB-TACE efficacy. Camptothecin (CPT), an NRF2 inhibitor, exerts chemosensitizing effects. We designed a controlled experiment to determine the efficacy and feasibility of DEB-TACE combined with CPT for the treatment of rabbit VX2 hepatoma. DEB-TACE activated NRF2 expression in the tumor region. NRF2 activation could be inhibited by the combined use of CPT. After DEB-TACE alone, the tumor necrosis was incomplete, there were still highly active tumor residues, and the apparent diffusion coefficient (ADC) value, which was negatively correlated with tumor activity observed by magnetic resonance imaging, remained low. After DEB-TACE combined with CPT, the relative necrosis of the tumor was more complete, the ADC value was higher, and the ADC change was greater. The single application of CPT did not result in evident liver function and physical burden to the rabbits. The combined use of CPT and DEB-TACE did not significantly increase DEB-TACE imaging of liver function and body. In conclusion, CPT can also inhibit high NRF2 expression after DEB-TACE treatment. Combining CPT with DEB-TACE can improve the sensitivity of DEB-TACE in the treatment of VX2 tumors, improve the therapeutic effect, and has no evident toxic and side effects. This study explored the methods for enhancing the efficacy of DEB-TACE in liver cancer from a new perspective and performed model experiments, which provided a theoretical basis for future clinical treatment. |
| first_indexed | 2024-04-12T00:40:33Z |
| format | Article |
| id | doaj.art-8207e4825d5c44a8b80f12107c8185d6 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-12T00:40:33Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8207e4825d5c44a8b80f12107c8185d62022-12-22T03:55:02ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-10-011210.3389/fonc.2022.906971906971Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor modelFanguang Meng0Fanguang Meng1Yuyao Li2Yuyao Li3Qian Liu4Liwei Sun5Liwei Sun6Hankang Wang7Hankang Wang8Xiaodong Li9Xiaodong Li10Guijie Li11Feng Chen12Department of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medicine Imaging, Jinan, ChinaShandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaShandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaUndergraduate, Department of Clinical Medicine, Faculty of Clinical and Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang, ChinaDepartment of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medicine Imaging, Jinan, ChinaShandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medicine Imaging, Jinan, ChinaShandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medicine Imaging, Jinan, ChinaShandong First Medical University & Shandong Academy of Medical Sciences, Jinan, ChinaDepartment of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medicine Imaging, Jinan, ChinaDepartment of Radiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Abdominal Medicine Imaging, Jinan, ChinaDrug-eluting bead transarterial chemoembolization (DEB-TACE) has been widely used in the treatment of liver cancer; however, the utilization rate of chemotherapeutic drugs after embolization is low. Chemotherapy resistance mediated by high nuclear factor E2-related factor 2 (NRF2) expression limits DEB-TACE efficacy. Camptothecin (CPT), an NRF2 inhibitor, exerts chemosensitizing effects. We designed a controlled experiment to determine the efficacy and feasibility of DEB-TACE combined with CPT for the treatment of rabbit VX2 hepatoma. DEB-TACE activated NRF2 expression in the tumor region. NRF2 activation could be inhibited by the combined use of CPT. After DEB-TACE alone, the tumor necrosis was incomplete, there were still highly active tumor residues, and the apparent diffusion coefficient (ADC) value, which was negatively correlated with tumor activity observed by magnetic resonance imaging, remained low. After DEB-TACE combined with CPT, the relative necrosis of the tumor was more complete, the ADC value was higher, and the ADC change was greater. The single application of CPT did not result in evident liver function and physical burden to the rabbits. The combined use of CPT and DEB-TACE did not significantly increase DEB-TACE imaging of liver function and body. In conclusion, CPT can also inhibit high NRF2 expression after DEB-TACE treatment. Combining CPT with DEB-TACE can improve the sensitivity of DEB-TACE in the treatment of VX2 tumors, improve the therapeutic effect, and has no evident toxic and side effects. This study explored the methods for enhancing the efficacy of DEB-TACE in liver cancer from a new perspective and performed model experiments, which provided a theoretical basis for future clinical treatment.https://www.frontiersin.org/articles/10.3389/fonc.2022.906971/fullhepatocellular carcinomaDEB-TACEchemoresistantNRF2camptothecinchemosensitization |
| spellingShingle | Fanguang Meng Fanguang Meng Yuyao Li Yuyao Li Qian Liu Liwei Sun Liwei Sun Hankang Wang Hankang Wang Xiaodong Li Xiaodong Li Guijie Li Feng Chen Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model Frontiers in Oncology hepatocellular carcinoma DEB-TACE chemoresistant NRF2 camptothecin chemosensitization |
| title | Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model |
| title_full | Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model |
| title_fullStr | Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model |
| title_full_unstemmed | Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model |
| title_short | Experimental study of camptothecin combined with drug-eluting bead transarterial chemoembolization in the rabbit VX2 liver tumor model |
| title_sort | experimental study of camptothecin combined with drug eluting bead transarterial chemoembolization in the rabbit vx2 liver tumor model |
| topic | hepatocellular carcinoma DEB-TACE chemoresistant NRF2 camptothecin chemosensitization |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.906971/full |
| work_keys_str_mv | AT fanguangmeng experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT fanguangmeng experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT yuyaoli experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT yuyaoli experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT qianliu experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT liweisun experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT liweisun experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT hankangwang experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT hankangwang experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT xiaodongli experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT xiaodongli experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT guijieli experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel AT fengchen experimentalstudyofcamptothecincombinedwithdrugelutingbeadtransarterialchemoembolizationintherabbitvx2livertumormodel |